This trial is active, not recruiting.

Condition cerebral palsy
Treatment pih
Phase phase 2/phase 3
Sponsor Sorlandet Hospital HF
Start date March 2004
End date December 2017
Trial size 20 participants
Trial identifier NCT00202761, SSHF70339


The purpose of this study is to document that taking part in this program is beneficial for the child, its parents and local professionals.

The study hypothesis are:

Intensive training will speed up the childs motor, cognitive and social development.

Intensive habilitation will increase the childs family's empowerment Children having participated in this intensive habilitation will speed up their process of development further than children in the control group The cooperation between first and second line health service is strengthened by participation in the intensive habilitation program The professionals in the first line(community)in Norway that participates in this program increases their empowerment and motivation

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification pharmacokinetics study
Intervention model single group assignment
Masking open label
Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
Intensified training

Primary Outcomes

time frame: dec 2006

Secondary Outcomes

time frame: Dec 2006

Eligibility Criteria

Male or female participants up to 5 years old.

Inclusion Criteria: About three years of age Cerebral Palsy Multidisciplinary diagnosed - Exclusion Criteria: Not have Pervasive Developmental Disorder (PDD) No Specific Speech and Language Disorders No Serious Sensory Defects -

Additional Information

Official title Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities
Principal investigator Jon Skranes, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Sorlandet Hospital HF.